<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629340</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19020231</org_study_id>
    <secondary_id>R01AG058659</secondary_id>
    <nct_id>NCT03629340</nct_id>
  </id_info>
  <brief_title>Metformin for Pulmonary Hypertension HFpEF</brief_title>
  <acronym>PH-HFpEF</acronym>
  <official_title>Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc A. Simon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the clinical efficacy of metformin versus
      placebo and the therapeutic response with regards to functional capacity and hemodynamics in
      PH-HFpEF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week blinded cross over trial of metformin in PH-HFpEF to improve exercise
      hemodynamics, functional capacity, and glucose metabolism. This phase II clinical trial will
      provide detailed phenotyping, physiological and mechanistic data on PH-HFpEF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the trial will be mean pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and metformin at 12 weeks (i.e. the week 12 RHC of placebo vs week 12 RHC of metformin).</measure>
    <time_frame>12 weeks (i.e. the 12th week of placebo vs 12th week of metformin)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Drug: Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks</description>
    <arm_group_label>Drug: Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        2. PH-HFpEF Confirmed diagnosis by RHC within the past 6 months:

        Mean Pulmonary Arterial Pressure (mPAP) ≥ 25 mm Hg AND Pulmonary artery wedge pressure
        (PAWP) ≥ 15 mm Hg AND Transpulmonary Gradient (TPG) ≥ 12 mm Hg

        OR Exercise measurements

        Mean Pulmonary Arterial Pressure (mPAP) ≥ 30 mm Hg AND Pulmonary artery wedge pressure
        (PAWP) ≥ 20 mm Hg AND PA calculation (change in mPAP/change in cardiac output) = ≥3
        mmHg/L/min

        3. Three or more features of metabolic syndrome defined as:

        Body Mass Index (BMI) ≥ 30 kg/m² Systolic blood pressure (BP) ≥ 130 mm Hg and/or diastolic
        BP ≥ 85 mm Hg Elevated waist circumference &gt; 102 cm in men and &gt; 88 cm in women Fasting
        triglyceride (TG) level over 150 mg/dl High-density lipoprotein &lt;40 mg/dL in men or &lt; 50
        mg/dL in women

        Exclusion Criteria:

          1. Age less than 18 years;

          2. Uncontrolled systemic hypertension based on repeated measurement of sitting systolic
             blood pressure &gt;170 mm Hg or sitting diastolic blood pressure &gt;95 mm Hg at Screening;

          3. Systemic sitting blood pressure &lt; 110 mmHg systolic or &lt; 60 mm Hg diastolic at
             Screening;

          4. Hemoglobin A1C &gt; 10;

          5. Currently taking metformin or history of intolerance to metformin or contraindication
             to taking metformin;

          6. Known type 1 diabetes

          7. Positive urine pregnancy test or breastfeeding

          8. Ejection Fraction &lt; 50%

          9. Dementia;

        11. End-stage malignancy; 12. Major cardiovascular event or procedure within 6 weeks prior
        to enrollment; 13. Severe valvular disease; 14. Other severe acute or chronic medical,
        psychiatric or laboratory abnormality that may increase the risk associated with study
        participation or investigational product administration or may interfere with the
        interpretation of study results and, in the judgment of the investigator, would make the
        subject inappropriate for entry into this study or would prevent completion of the study;
        15. Current Smoker; 16. Hemoglobin &lt;9 g/dL; 17. Estimated glomerular filtration rate (eGFR)
        &lt;30 mL/min/1.73 m2; 18. Receipt of an investigational product or device, or participation
        in a drug research study within a period of 15 days 19. &lt;3 months of stable dose of PDE5i
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Simon, MD, MS, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Onesi, RN</last_name>
    <phone>412-864-3265</phone>
    <email>onesisa@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Helbling, MS, BSN, RN</last_name>
    <phone>412-692-2285</phone>
    <email>helblingnl@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Onesi, RN</last_name>
      <phone>412-864-3265</phone>
      <email>onesisa@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Marc A. Simon</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

